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This paper presents the results of a large and 
well-designed randomised trial, which 
examined the effectiveness of an injection of
cefuroxime 1 mg in the anterior chamber at 
the conclusion of cataract surgery. The results 
showed such a great benefit from the use of 
cefuroxime that the trial was stopped early, 
because it was considered unethical not to 
use the treatment.
From these figures, out of 10,000 cataract 
operations without postoperative intracameral 
cefuroxime, 23.3 would be expected to develop 
culture-positive endophthalmitis. With intrac-
ameral cefuroxime, this number would only be 
4.4 (OR=5.32, 95%; CI 1.55–18.26). 
Globally, 10 million cataract operations are 
performed every year. This gives an incidence 
of endophthalmitis of 23,000 per year. If all 
surgeons used intracameral cefuroxime in 
every case, the incidence of endophthalmitis 
would be reduced to 4,400.
What about toxicity? It appears that the 
intracameral injection of cefuroxime is not 
toxic: Swedish researchers have published 
results on many thousands of eyes that have 
received intracameral cefuroxime without 
any adverse effects.1
It is possible that these results on the 
prophylactic effect of intracameral cefuroxime 
might be different in developing countries. This 
study was carried out in Europe, and it was also 
carried out on eyes that were having phaco-
emulsification. It is likely that the majority of 
these eyes had clear corneal incisions, with no 
sutures. Few clinics in developing countries 
routinely use phacoemulsification.They tend to 
favour extracapsular extraction, a technique in 
which the wound is covered with a conjunctival 
flap and which may be associated with a lower 
risk of infection. However, since the type of 
wound closure is not the only factor in the 
occurrance of endophthalmitis, similar prophy-
lactic results may be obtained with the 
intracameral injection of cefuroxime at the end 
of extracapsular cataract extraction. 
Despite these uncertainties, this study 
represents the best evidence we have regarding 
the prevention of this devastating complication.
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Purpose: To report results of the European Society of Cataract 
& Refractive Surgeons (ESCRS) multicentre study of the 
prophylaxis of endophthalmitis after cataract surgery. 
Setting: Twenty-four ophthalmology units and eye clinics in 
Austria, Belgium, Germany, Italy, Poland, Portugal, Spain, Turkey, 
and the United Kingdom, with an administrative office in Ireland, a 
coordinating centre in England, and a data management and 
statistical unit in Scotland.
methods: This partially masked randomised placebo-controlled 
multinational clinical study aimed to evaluate prospectively the 
prophylactic effect of an intracameral cefuroxime injection and/or 
perioperative levofloxacin eyedrops on the incidence of endoph-
thalmitis after phacoemulsification cataract surgery. The study 
began in September 2003 and was terminated early in January 
2006. The study used random allocation of patients in a 2x2 
factorial design.
results: By the end of 2005, complete follow-up records had 
been received for 13,698 study patients. Such a clear beneficial 
effect from the use of intracameral cefuroxime had been observed 
that it was agreed it would be unethical to continue the study and 
to wait for the completion of all follow-up procedures before 
reporting this important result. If total reported cases of endoph-
thalmitis are considered, the incidence rate observed in those 
treatment groups not receiving cefuroxime prophylaxis (23 cases 
in 6,862 patients) was almost five times as high (odds ratio [OR] 
4.59; 95% confidence interval [CI] 1.74–12.08; p=0.002) as 
that in the groups receiving this treatment (5 cases in 6,836 
patients). If only cases proved to be due to infection are 
considered, the rate was more than five times as high (OR 5.32; 
95% CI 1.55–18.26; p=0.008) in the treatment groups not 
receiving cefuroxime. Although the use of perioperative 
levofloxacin eyedrops as prophylaxis was also associated with a 
reduction in the observed incidence rate of postoperative endoph-
thalmitis, this effect was smaller and was not statistically significant, 
whether total reported cases or only cases proven to be due to 
infection were used in calculating the rates. As not all follow-up 
procedures are complete, it is possible that further cases of 
endophthalmitis may be reported; however, it is not expected that 
this will alter the main conclusion. Nevertheless, it is anticipated 
that successful completion of follow-up procedures in all patients 
will increase the total number in the study to approximately 16,000.
Conclusion: Intracameral cefuroxime administered at the time of 
surgery significantly reduced the risk for developing endoph-
thalmitis after cataract surgery. 
You will need the following:
Vial of 250 mg cefuroxime •	
2x10 ml normal saline •	
2 ml syringe •	
1 ml syringe •	
Method
1  Dissolve the cefuroxime in 
12.5 ml of normal saline 
(20 mg/ml)
2  Draw up 1 ml of the 
cefuroxime solution (20 mg) 
in the 2 ml syringe
3  Make up to 2 ml with 1 ml 
normal saline (10 mg/ml)
4  Draw up 0.1 ml of this 
solution (1 mg) with the 
1 ml syringe and inject into 
the anterior chamber, 
using a Rycroft cannula, 




Barry P, seal DV, Gettinby G, Lees F, Peterson M, Revie CW; esCRs endophthalmitis study Group 
ESCRS study of prophylaxis of postoperative endophthalmitis after cataract 
surgery: preliminary report of principal results from a European multicenter study
J Cataract Refract Surg 2006 Mar;32(3): 407–10
Comment